June 13, 2025

Riva Returns!

Luigi Mondello explains why the time is right to reignite Chromatography’s much-missed “scientific retreat”

The Analytical Scientist

June 13, 2025

The Special Series HPLC E-book

Are we still pushing the limits of liquid chromatography? Absolutely, say our experts – who continue to surf on the edge of LC innovation – as part of our special collection of recent HPLC insights.

The Analytical Scientist

June 13, 2025

JAK Inhibitors Show No Increased Cancer Risk

New real-world data show no significant rise in overall cancer incidence with JAK inhibitors for rheumatoid arthritis patients, though skin cancer monitoring remains important.

Conexiant

June 10, 2025

FDA Pledges Week-Long Drug Reviews

New leadership outlines accelerated approval processes, AI integration, and food additive restrictions to address the chronic disease epidemic

Conexiant

June 09, 2025

NIH Staff Challenge Leadership's Research Policies

Federal scientists release formal dissent declaration opposing administration's grant terminations and policy changes affecting biomedical research.

Conexiant

June 09, 2025

Appendix Tumors Climb for Millennials, Gen Z

Younger generations—particularly individuals born after 1980—face higher rates of appendiceal cancer, with incidence increasing more than fourfold in recent decades, according to a new study.

Conexiant

June 05, 2025

Investigational Menin Inhibitor Under Study in NPM1-Mutant AML

The investigational agent ziftomenib, a menin-MLL inhibitor, demonstrated activity in patients with relapsed or refractory NPM1-mutant acute myeloid leukemia (AML), regardless of prior venetoclax trea...

The ASCO Post

June 05, 2025

Novel Antibody-Drug Conjugate for Newly Diagnosed BPDCN

A first-in-class antibody-drug conjugate was found to be safe and effective for patients with blastic plasmacytoid dendric cell neoplasm (BPDCN), according to data from a phase I/II study.

The ASCO Post

June 04, 2025

Stroke Risk in Down Syndrome: Underestimated?

A large population study found that individuals with Down syndrome face a significantly higher risk of stroke, particularly at younger ages, while their risk of heart attack is generally similar to the general population but elevated before age 40.

Conexiant